Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
25
11
2022
received:
28
08
2022
accepted:
06
12
2022
pubmed:
3
1
2023
medline:
17
2
2023
entrez:
2
1
2023
Statut:
ppublish
Résumé
Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, that predominately affects the elderly. We report the outcomes of young WM patients, evaluated over five decades, compared to their older counterparts, matched for the time of diagnosis. Between January 1, 1960 and October 31, 2013, 140 (11.8%) WM patients were ≤50 years of age at diagnosis in our database, and their estimated 10-year overall survival (OS) was 74%, with death attributable to WM in a higher proportion of patients compared to their older (≥65 years) counterparts (91% vs. 58%, p = .0001). Young patients were grouped into three cohorts based on the timing of the initiation of therapy: Group 1 (1960-1977, n = 12), Group 2 (1978-1995, n = 48), and Group 3 (1996-2013, n = 74). Among young patients, there was no disease-specific survival (DSS) difference across the three periods, [median DSS at 13 years (95% CI 5-23), 16 years (95% CI 14-22), and 15 years (95% CI 10-NR; p = .41), respectively]. However, DSS for the older cohort incrementally improved (Group 1, median 5.2 years, Group 2: 9.6 years, Group 3: 12 years; p = .05) over these periods. The estimated average years-of-life lost for the young cohort was 11.2 years from diagnosis, based on the expected survival for a normal age- and sex-matched population. Despite a protracted disease course, nearly all young patients succumb to their disease. In contrast to the improved survival of the elderly patient population, the evolving treatment strategies in WM have not impacted the outcome of young patients; however, the impact of Bruton tyrosine kinase inhibitors on this unique patient population remains to be determined.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
432-439Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-5032.
Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012;118(15):3793-3800.
Kyle RA, Larson DR, McPhail ED, et al. Fifty-year incidence of Waldenstrom Macroglobulinemia in Olmsted County, Minnesota, from 1961 through 2010: a population-based study with complete case capture and hematopathologic review. Mayo Clin Proc. 2018;93(6):739-746.
Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006;133(2):158-164.
Buske C, Leblond V. How to manage Waldenstrom's macroglobulinemia. Leukemia. 2013;27(4):762-772.
Yin X, Chen L, Fan F, et al. Trends in incidence and mortality of Waldenstrom Macroglobulinemia: a population-based study. Front Oncol. 2020;10:1712.
Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163-4170.
Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008;67(2):124-132.
Pophali PA, Bartley A, Kapoor P, et al. Prevalence and survival of smouldering Waldenstrom macroglobulinaemia in the United States. Br J Haematol. 2019;184(6):1014-1017.
Olszewski AJ, Treon SP, Castillo JJ. Evolution of management and outcomes in Waldenstrom macroglobulinemia: a population-based analysis. Oncologist. 2016;21(11):1377-1386.
Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18(2):241-250.
Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015;372(15):1430-1440.
Kastritis E, Zervas K, Repoussis P, et al. Prognostication in young and old patients with Waldenstrom's macroglobulinemia: importance of the international prognostic scoring system and of serum lactate dehydrogenase. Clin Lymphoma Myeloma. 2009;9(1):50-52.
Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood. 2012;119(19):4462-4466.
Nelson S, Boise LH, Kaufman JL, et al. Changing Epidemiology and Improved Survival in Patients with Waldenstrom Macroglobulinemia: Review of Surveillance, Epidemiology, and End Results (SEER) Data. Blood. 2013;122(21):3135.
Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database. Br J Haematol. 2015;169(1):81-89.
Human Mortality Database. Accessed November, 2016.
Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenström's macroglobulinemia. Ann Oncol. 2006;17(3):488-494.
Treon SP, Meid K, Hunter ZR, et al. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia. Blood. 2021;138(17):1535-1539.
Zanwar S, Abeykoon JP, Ansell SM, et al. Characteristics and outcome of patients with MYD88 wild-type Waldenström Macroglobulinemia. J Clin Oncol. 2020;38(15_suppl):8550.
Treon SP, Gustine J, Xu L, et al. MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018;180(3):374-380.
Zanwar S, Abeykoon JP, Ansell SM, et al. Disease outcomes and biomarkers of progression in smouldering Waldenstrom macroglobulinaemia. Br J Haematol. 2021;195(2):210-216.
Varettoni M, Ferrari A, Frustaci AM, et al. Younger patients with Waldenstrom macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. Am J Hematol. 2020;95(12):1473-1478.
Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31(3):301-307.
Chen CI. Treatment for Waldenstrom's macroglobulinemia. Ann Oncol. 2004;15(4):550-558.
Michallet M, Thiebaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol. 2000;108(3):595-601.
Lukenbill J, Kalaycio M. Fludarabine: a review of the clear benefits and potential harms. Leuk Res. 2013;37(9):986-994.
Gunaratne M, Sahakian AJ, Abeykoon JP, et al. Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2021;62(2):308-315.